IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
about
Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15Adoptive immunotherapy for cancer: building on successIL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cellsThe 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responsesBreaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.Different Subsets of T Cells, Memory, Effector Functions, and CAR-T ImmunotherapyMelanoma: oncogenic drivers and the immune systemAnticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12IL-15-PI3K-AKT-mTOR: A Critical Pathway in the Life Journey of Natural Killer CellsApplication of IL-2 therapy to target T regulatory cell functionTargeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapyLow-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunityFrom IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokinesCheckpoint modulation--A new way to direct the immune system against renal cell carcinomaSuppression, subversion and escape: the role of regulatory T cells in cancer progressionFoxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis CImmunosuppression associated with chronic inflammation in the tumor microenvironmentIL15 and T-cell Stemness in T-cell-Based Cancer ImmunotherapyImmunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administrationTargeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy.Regulatory T cells in AKI.Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapyTrends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapyDose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.Engineered T cells for cancer treatmentInterleukin-7 and Immunosenescence.Re-adapting T cells for cancer therapy: from mouse models to clinical trials.The use of immunotherapy in the treatment of melanomaThe role of regulatory T cells in cancer.Vaccines against human carcinomas: strategies to improve antitumor immune responses.What's the place of immunotherapy in malignant mesothelioma treatments?Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.Trial watch: Immunostimulatory cytokines in cancer therapy.
P2860
Q24301975-DE1267C6-1E9C-4417-8BCC-F086075E0BDCQ24546258-57C3DD8E-7F44-4966-8344-88B3403FF447Q24546362-EF7D66ED-6565-4CAF-BC4A-3D145C11868DQ24616434-C1A91A14-2101-4E3C-866E-43A71A0B1F51Q26744624-D72E8992-F8C4-4176-8011-F3BB4A66CF2CQ26752955-275168F0-3EC1-4806-9208-6F54C66B5277Q26775598-2C41B982-8233-4AB4-B128-643FF646B74AQ26796316-694E2B07-A246-45BA-BACF-AB58FFF0E719Q26800159-497D48A6-E46E-484B-992B-3618FE840B32Q26827327-F5A6B641-AB80-498B-95B8-C01F4B35BB44Q26991589-E0671BC7-E2AD-433F-B027-67B4A818A06CQ27008200-C3BC8768-89FE-4197-ABBE-CF8900DAAB12Q27008912-06F26E6F-6830-4F9E-8D2C-FF9CEDFC7D8BQ27025873-522D4142-F676-432A-8F0E-8AA272946C40Q27026151-EE2283F7-5DF0-4CBA-BCBC-C40A1B376908Q27480306-D2EF8A47-6E0F-4A9D-B13B-A26ABD09F980Q28083450-80840DB7-8DA8-48A6-8267-3C523E949655Q28088543-CB7D0BCD-2B8B-4D95-BF5C-B9E9C493E7EDQ28301672-51C6D961-EB1B-4421-80A4-70DD675967FAQ28732675-02DD8C13-3A8C-478B-88CD-985FA1FE6F29Q30252860-473A2395-0856-4675-8C87-1F8342461378Q30409790-E6A0EC1F-8F47-44A9-BE85-EB379B311C70Q33282703-99D3C986-008A-47AD-B0CA-06D10C59F0C5Q33311571-3E8BAD62-F73A-470F-A767-EE40AD527263Q33320890-265BC0CD-0EDC-4582-A533-63A2232599AAQ33373073-9DDC5D1A-FC5E-4FBD-9E40-308A053C5616Q33417698-231BF547-9A76-4B69-9413-B0A61179F43EQ33418729-AB57EAC3-B3A1-4DEA-B237-26C50DCA874AQ33578792-FF30026C-2B6F-4D27-A10E-3CC803A150BEQ33582101-2761429F-356A-4BC7-9E7B-E01FD9169AA6Q33588711-AF130133-2921-43EE-9AF2-DD78134CFC70Q33593858-8F4DB727-FF49-4289-B8F2-51549AD7F641Q33631986-B0EA38A4-92A6-4B17-A180-F42B640971D2Q33734281-6B40B6EE-7CE1-42AC-805A-404E8E7A2002Q33781142-C8E003B8-FDA6-4B4B-AE60-DD1834AFA6B4Q33811204-9287CEA4-452F-4AF4-9ED6-5AC3E4DA3F01Q33815631-CD2386F5-C520-4BE7-9949-46B61F518E62Q33861833-5C551BCA-3036-4970-951B-6478C7361A99Q33870728-1C57743D-0D8A-4923-8AC6-EEBF02E55C13Q33880165-852D638C-CD0C-443C-9411-5BD3FAE26B3D
P2860
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
IL-2 administration increases CD4+ CD25
@nl
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
@ast
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
@en
type
label
IL-2 administration increases CD4+ CD25
@nl
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
@ast
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
@en
prefLabel
IL-2 administration increases CD4+ CD25
@nl
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
@ast
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
@en
P2860
P1433
P1476
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
@en
P2093
Mojgan Ahmadzadeh
Steven A Rosenberg
P2860
P304
P356
10.1182/BLOOD-2005-06-2399
P407
P577
2005-11-22T00:00:00Z